NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 143)
Posted On: 08/13/2019 4:36:55 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Subsidiary Receives Health Canada Cannabis R&D License
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that Health Canada has issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to its subsidiary, Lexaria CanPharm ULC. According to the update, the license, which carries a four-year term unless renewed, is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in THC and CBD delivery using optimized, proprietary formulations and techniques. The purpose-built laboratory is permitted at local and federal levels and fully outfitted to produce DehydraTECH(TM) infusions and includes two different methodologies by which the company can create nano-sized molecules when deemed beneficial. “Receipt of our R&D License from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our Company’s history,” Lexaria President and Chief Scientist John Docherty said in the news release. “This license will greatly enhance our ability to work with cannabis Licensed Producers to perform work in-house on customized formulations that could benefit each of Canada’s licensed cannabis companies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that Health Canada has issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to its subsidiary, Lexaria CanPharm ULC. According to the update, the license, which carries a four-year term unless renewed, is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in THC and CBD delivery using optimized, proprietary formulations and techniques. The purpose-built laboratory is permitted at local and federal levels and fully outfitted to produce DehydraTECH(TM) infusions and includes two different methodologies by which the company can create nano-sized molecules when deemed beneficial. “Receipt of our R&D License from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our Company’s history,” Lexaria President and Chief Scientist John Docherty said in the news release. “This license will greatly enhance our ability to work with cannabis Licensed Producers to perform work in-house on customized formulations that could benefit each of Canada’s licensed cannabis companies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼